Sanofi Canada invests in prostate cancer research - Collaboration with the GU Radiation Oncology Group of Quebec and the Segal Cancer Centre at the Jewish General Hospital (JGH)

MONTREAL, April 26, 2012 /CNW Telbec/ - Sanofi Canada is supporting a five-year study on radiation therapy and prostate cancer. Dr. Tamim Niazi (centre left), of the Quebec Radiation Oncology GU Group and the JGH, is the lead researcher. Sanofi Canada President and CEO, Hugh O'Neill (centre right) and members of Sanofi's Oncology Team celebrate the collaboration.

Image with caption: "Sanofi Canada is supporting a five-year study on radiation therapy and prostate cancer. Dr. Tamim Niazi (centre left), of the Quebec Radiation Oncology GU Group and the JGH, is the lead researcher. Sanofi Canada President and CEO, Hugh O'Neill (centre right) and members of Sanofi's Oncology Team celebrate the collaboration. (CNW Group/SANOFI CANADA)". Image available at: http://photos.newswire.ca/images/download/20120426_C9224_PHOTO_EN_12750.jpg